Eosinophils are a type of white blood cell. The body produces them as part of the immune response, and elevated counts are often linked to allergic conditions, including certain forms of asthma. When eosinophils are chronically elevated, researchers consider that a sign of ongoing inflammatory activity. The question of what drives those counts up or down is an active area of investigation.
A real-world study published in BMC Pulmonary Medicine set out to measure whether treatment with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), changed blood eosinophil counts in a population of adults. The researchers were motivated in part by earlier signals in the scientific literature suggesting that GLP-1 receptor agonists might have effects on airway inflammation, particularly in eosinophilic asthma phenotypes.
The study enrolled 371 participants seen at a single outpatient clinic in Shanghai, China, making it one of the more substantial real-world datasets to examine this specific question. Because it drew on electronic medical records rather than a controlled experimental setting, it reflects how the peptide performs outside of a tightly managed clinical trial, which adds a different kind of value to the evidence base.
What eosinophils do and why the count matters
Eosinophils make up a small fraction of circulating white blood cells in healthy adults, typically sitting below 5 percent of the total white cell count. They are part of the innate immune system and become more active during allergic reactions, parasitic infections, and certain inflammatory conditions.
A blood eosinophil count (BEC) above 150 cells per microliter is increasingly used in respiratory medicine as a threshold that signals elevated eosinophilic inflammation. People with counts above that level are sometimes categorized as having an eosinophilic phenotype, which can influence treatment decisions in conditions like asthma. The study authors chose that 150 cells per microliter cutoff as one of their main stratification points precisely because it carries clinical meaning in the published literature.
How the study was designed
The researchers conducted a retrospective, single-center study. That means they looked backward through existing medical records rather than assigning participants to different treatment arms going forward. All participants had been prescribed semaglutide for the first time at the clinic, primarily for glycemic control or weight management. Demographic details, complete blood counts, and lipid profiles were collected both before and after the treatment period.
Participants were divided into subgroups based on two thresholds. The first was the 150 cells per microliter BEC cutoff, separating those with lower versus higher baseline eosinophil counts. The second was a body mass index threshold of 28 kilograms per square meter, a cutoff commonly used in Chinese clinical guidelines to distinguish between non-obese and obese individuals. The team then used multiple linear regression to look for variables that independently predicted how much a person's eosinophil count would change.
The core findings on eosinophil counts
Across all 371 participants, blood eosinophil counts dropped significantly after semaglutide treatment. The median count fell from 160 cells per microliter at baseline to 110 cells per microliter afterward, a statistically significant reduction with a p-value below 0.001. Eosinophil percentage of total white blood cells declined in parallel, moving from a median of 2.20 percent down to 1.60 percent.
Perhaps most notably, the proportion of participants whose counts sat above the 150 cells per microliter threshold fell substantially. Before treatment, 55.80 percent of participants had counts at or above that level. After treatment, that figure dropped to 34.21 percent, meaning the share of participants below 150 cells per microliter climbed from 44.20 percent to 65.79 percent.
The reduction was observed in both subgroups defined by baseline eosinophil levels. People who started with counts below 150 cells per microliter still showed a measurable decrease, and those who started at or above 150 cells per microliter showed an even more pronounced one. That consistency across baseline levels was one of the more striking aspects of the dataset.
The role of body weight in the response
When the researchers split participants by the BMI threshold of 28 kilograms per square meter, a difference in the magnitude of eosinophil reduction emerged. The lower-BMI group showed a median percentage reduction in eosinophil count of approximately 31.58 percent, compared to 21.04 percent in the higher-BMI group. That difference was statistically significant at p equal to 0.037.
The literature suggests that adipose tissue itself plays a role in inflammatory signaling, which could offer one possible frame for this finding. Whether the difference reflects something about how the peptide interacts with immune pathways differently across body compositions, or whether it is mediated through other metabolic variables, is not something this observational study can resolve. The authors note it as a finding that warrants further investigation.
What the regression analysis identified
Multiple linear regression is a statistical method that tries to isolate which variables are independently associated with an outcome after accounting for the influence of other variables simultaneously. In this study, the regression was used to identify predictors of eosinophil count reduction after semaglutide treatment, with BMI and lipid parameters included as covariates.
The only variable that came out as an independent predictor of greater eosinophil reduction was baseline eosinophil count itself. In other words, after adjusting for BMI and lipid-related factors, the strongest signal for how much someone's count would drop was simply how high it was to begin with. BMI appeared to modify the size of the effect in descriptive analysis, but it did not survive as an independent predictor in the regression model once baseline count was included. This finding aligns with a broader principle seen across many biological measurements: the further from a set-point a value starts, the more room it has to move.
Limitations and what comes next
Because this was a retrospective, single-center, real-world study without a control group, it cannot establish causation. Participants were not randomized, and there may be unmeasured variables that influenced both who received the peptide and how their eosinophil counts changed. The researchers also did not report follow-up data on respiratory symptoms or asthma outcomes, so the clinical significance of the observed count reductions remains an open question.
The study's registration with the Chinese Clinical Trial Registry and its publication in a peer-reviewed journal add credibility to the dataset, but prospective trials with control arms will be needed before firmer conclusions can be drawn. The authors frame this as hypothesis-generating work, suggesting that GLP-1 receptor agonists deserve attention in the context of eosinophilic airway disease research. Early data points at a meaningful biological signal, but the mechanism connecting GLP-1 receptor activation to eosinophil biology is not yet fully characterized in the published literature.
